---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-24-002415"
form_type: "8-K"
ticker: "NXL"
cik: "0001527352"
company_name: "Nexalin Technology, Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:01:16.749925+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nexalin CEO details clinical progress, Gen-3 HALO headset, and government market expansion

## Summary
- Positive clinical results from UCSD study: Gen-2 tACS reduced post-concussive and PTSD symptoms in veterans with mTBI.
- Published insomnia study showed statistically significant sleep improvements vs placebo; 6 additional peer-reviewed studies on 15mA waveform.
- New Gen-3 HALO Clarity headset with DIFS technology enables at-home treatment under Virtual Clinic remote physician monitoring; ahead of schedule.
- Formed military and government advisory board led by former Deputy Assistant Secretary of Defense; targeting DoD, VA, HHS markets.
- Received regulatory approval in Oman with sales to new Mental Health Center; patents extended through 2040 with four key patents and three pending.

## SEC filing metadata
- accession: 0001829126-24-002415
- form_type: 8-K
- ticker: NXL
- cik: 0001527352
- company_name: Nexalin Technology, Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527352/000182912624002415/0001829126-24-002415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527352/000182912624002415/nexalintechno_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-24-002415
- JSON: https://secwatch.observer/filing/0001829126-24-002415.json
- Plain text: https://secwatch.observer/filing/0001829126-24-002415.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.